GlobeNewswire

Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates

Share

WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2018.

"Minerva now has five late-stage clinical efficacy trials ongoing with three compounds," said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva.  "These include our lead product, roluperidone (MIN-101) for schizophrenia, MIN-117 for MDD and seltorexant (MIN-202) for insomnia disorder and MDD. 

"In schizophrenia, the leading unmet medical need as ranked by psychiatrists is negative symptoms, the target indication for roluperidone," said Dr. Luthringer.  "Based on the improvement in negative symptoms measured in clinical tests with roluperidone to date, combined with the observed stability in positive symptoms and a favorable side effect profile, we believe this compound has the potential to be a differentiated therapy in schizophrenia, and we are working on commercialization strategies that address this significant commercial opportunity."

Clinical Development Updates

Roluperidone (MIN-101):

  • The Company's clinical sites in the U.S. are actively enrolling patients in the pivotal Phase 3 trial with roluperidone.  The Company has prioritized the initiation of U.S. sites, and now European sites have been initiated. Target enrollment in this trial is approximately 500 patients.  Top-line results are expected in the first half of 2019.

MIN-117:

  • As announced on April 9, 2018, the Company has enrolled the first patient in a Phase 2b trial of MIN-117 to treat the symptoms of patients diagnosed with MDD.  Approximately 324 patients will be enrolled at clinical sites in the U.S. and Europe. Top-line results are expected in the first half of 2019.

Seltorexant (MIN-202 or JNJ-42847922), under joint development with Janssen Pharmaceutica NV (Janssen):

  • Three Phase 2b clinical trials are ongoing with seltorexant, including two in MDD and one in insomnia disorder.  In the first MDD trial, approximately 280 patients are planned to be enrolled at clinical sites in the U.S., Europe and Japan.  In the second MDD trial, approximately 100 patients are planned to be randomized at clinical sites in the U.S.  The insomnia trial is expected to enroll a total of approximately 360 patients at clinical sites in the U.S., Europe and Japan. These trials are planned for completion in 2019.

First Quarter 2018 Financial Results

  • Net Loss:  Net loss was $12.4 million for the first quarter of 2018, or a loss per share of $0.32 (basic and diluted), compared to a net loss of $10.6 million for the first quarter of 2017, or a loss per share of $0.30 (basic and diluted).
     
  • R&D Expenses: Research and development (R&D) expenses were $8.4 million in the first quarter of 2018, compared to $7.6 million in the first quarter of 2017.  The increase in R&D expenses primarily reflects higher development expenses for the Phase 3 clinical trial of roluperidone and the Phase 2b clinical trial of MIN-117. These amounts were partially offset by lower development expenses for the seltorexant program due to the amendment to the Company's Co-Development and License Agreement with Janssen.  R&D expenses are expected to increase during 2018 with increased patient enrollment and related support activities for the roluperidone and MIN-117 clinical trials.
     
  • G&A Expenses: General and administrative (G&A) expenses were $4.3 million in the first quarter of 2018, compared to $2.9 million in the first quarter of 2017. This increase in G&A expenses was primarily due to an increase in non-cash stock-based compensation expenses and salary costs from increased staffing to support the Company's pre-commerical activities.  G&A expenses are expected to increase during 2018 with investment in the infrastructure necessary to support the Company's growth.
     
  • Cash Position: Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2018 were approximately $121.1 million. 

Conference Call Information:

Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities.  To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 8885379.

The live webcast can be accessed under "Events and Presentations" in the Investors and Media section of Minerva's website at ir.minervaneurosciences.com.  The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva's proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."  For more information, please visit www.minervaneurosciences.com

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and scope of current clinical trials and results of clinical trials with roluperidone, seltorexant, MIN-117 and MIN-301; the timing and scope of future clinical trials and results of clinical trials with these compounds; the clinical and therapeutic potential of these compounds; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-Q for the quarter ended March 31, 2018, filed with the Securities and Exchange Commission on May 3, 2018.  Copies of reports filed with the SEC are posted on our website at  www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

   
CONDENSED CONSOLIDATED BALANCE SHEET DATA  
(Unaudited)  
  March 31, December 31,  
  2018     2017    
  (in thousands)  
ASSETS  
Current Assets:      
Cash and cash equivalents $   45,126   $   26,052    
Marketable securities     75,871       102,109    
Restricted cash     100       80    
Prepaid expenses and other current assets     4,243       1,299    
Total current assets     125,340       129,540    
Marketable securities - noncurrent     -        5,023    
Equipment, net     47       51    
Other noncurrent assets     15       15    
In-process research and development     34,200       34,200    
Goodwill     14,869       14,869    
Total Assets $   174,471   $   183,698    
       
LIABILITIES AND STOCKHOLDERS' EQUITY  
Current Liabilities:      
Notes payable $   2,697   $   3,962    
Accounts payable     2,825       1,436    
Accrued expenses and other current liabilities     2,393       1,439    
Total current liabilities     7,915       6,837    
Long-Term Liabilities:      
Deferred taxes     4,057       4,057    
Deferred revenue     41,176       41,176    
Other noncurrent liabilities     30       30    
Total liabilities     53,178       52,100    
Stockholders' Equity:      
Common stock     4       4    
Additional paid-in capital     298,089       295,975    
Accumulated deficit     (176,800 )     (164,381 )  
Total stockholders' equity     121,293       131,598    
Total Liabilities and Stockholders' Equity $   174,471   $   183,698    
       

 

 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)      
    Three Months Ended March 31,
    (in thousands, except per share amounts)
      2018     2017  
       
Revenues   $   -    $   -   
Operating expenses:      
Research and development       8,449       7,614  
General and administrative       4,294       2,871  
Total operating expenses       12,743       10,485  
       
Foreign exchange losses       (18 )     (17 )
Investment income       414       59  
Interest expense       (71 )     (202 )
Net income (loss)   $   (12,418 ) $   (10,645 )
Loss per share:      
Basic and diluted   $   (0.32 ) $   (0.30 )
Weighted average shares:      
Basic and diluted       38,749       35,370  
       

 

Contact :

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Vostok Emerging Finance buybacks during w.2923.7.2019 08:00:00 CESTPress release

Stockholm, July 23, 2019 (GLOBE NEWSWIRE) -- During the period July 15, 2019 until July 19, 2019, Vostok Emerging Finance Ltd (“VEF” or the “Company”) has repurchased in total 488,247 Swedish Depository Receipts (SDRs). The share buybacks have been made within the USD 5m buyback program announced by the Company on March 4, 2019. SDRs have been repurchased as follows during this period: Date Aggregated daily volume (number of SDRs) Weighted average SDR price per day (SEK) Total daily transaction value (SEK) July 15, 2019 95,700 2.47 235,962 July 16, 2019 97,500 2.45 239,125 July 17, 2019 104,000 2.47 256,835 July 18, 2019 106,000 2.45 259,811 July 19, 2019 85,047 2.48 210,715 All trades have been carried out on Nasdaq First North Stockholm by Pareto Securities AB on behalf of VEF. Following the above acquisitions, VEF holds 2,718,218 repurchased SDRs in the Company, and the total number of outstanding SDRs of the Company excluding repurchased SDRs is 658,777,777 and including repurchase

Better Collective acquires US market leading sports betting brands; VegasInsider.com and ScoresandOdds.com23.7.2019 08:00:00 CESTPress release

Regulatory Release 21/2019 Better Collective has, through a wholly-owned US subsidiary, completed the acquisition of the assets of Florida based Vegasinsider.com and Scoresandodds.com for a total transaction price of 20 million USD to be paid in cash. Better Collective, the world’s leading sports betting affiliate, has acquired two of the leading sports betting websites in the United States (US). The brands have been market leading within sports betting information for more than 20 years and are expected to become market leading affiliate websites in those states where online sports betting is available. During the National Football League (NFL) 2018/2019 season, the two websites generated more than 15 million unique visits per month. Changing the business model With the aim of empowering sports bettors worldwide, Better Collective is adding the two websites to its portfolio of sites to educate and entertain users in the US as various states are beginning to regulate online sports bett

Vostok Emerging Finance buybacks during w.2923.7.2019 08:00:00 CESTPressemelding

Stockholm, July 23, 2019 (GLOBE NEWSWIRE) -- During the period July 15, 2019 until July 19, 2019, Vostok Emerging Finance Ltd (“VEF” or the “Company”) has repurchased in total 488,247 Swedish Depository Receipts (SDRs). The share buybacks have been made within the USD 5m buyback program announced by the Company on March 4, 2019. SDRs have been repurchased as follows during this period: Date Aggregated daily volume (number of SDRs) Weighted average SDR price per day (SEK) Total daily transaction value (SEK) July 15, 2019 95,700 2.47 235,962 July 16, 2019 97,500 2.45 239,125 July 17, 2019 104,000 2.47 256,835 July 18, 2019 106,000 2.45 259,811 July 19, 2019 85,047 2.48 210,715 All trades have been carried out on Nasdaq First North Stockholm by Pareto Securities AB on behalf of VEF. Following the above acquisitions, VEF holds 2,718,218 repurchased SDRs in the Company, and the total number of outstanding SDRs of the Company excluding repurchased SDRs is 658,777,777 and including repurchase

Idorsia announces financial results for the first half of 201923.7.2019 07:00:00 CESTPress release

Allschwil, Switzerland – July 23, 2019 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2019. Key figures US GAAP operating expenses HY 2019 at CHF 252 million Non-GAAP operating expenses HY 2019 at CHF 234 million Unchanged guidance for 2019: US GAAP operating expenses of around CHF 570 million and non-GAAP operating expenses of around CHF 530 million (both measures exclude any potential milestone payments) Jean-Paul Clozel, MD and Chief Executive Officer, commented: “The first half of 2019 has been about running our studies and getting ready for the wave of results and news flow approaching soon. All departments are getting ready for the potential filing of our late stage assets. With the appointment of Simon Jose as Chief Commercial Officer the hiring of a core commercial team has begun, enabling the development of a commercial business plan. We expect to receive the first set of pivotal data in the first half of 2020.” Financial results US GAAP re

SIKA EXPANDS MORTAR PLANT IN SERBIA23.7.2019 07:00:00 CESTPress release

SIKA EXPANDS MORTAR PLANT IN SERBIA Sika is expanding its production capacities in Southeast Europe by bringing a further mortar facility as well as a warehouse for raw materials and end-products on stream at its Simanovci site in Serbia. The plant, which is located near Belgrade, has been continuously expanded in recent years to keep pace with the dynamic development experienced by the region’s construction sector and strong Sika growth. The expanded production capacities and new warehouse will enable Sika to continue to successfully penetrate the growing construction markets in Southeast Europe. The high-quality ready-mixed mortars produced at the site are distributed primarily to builders’ merchants. As well as catering for the domestic market, the ultra-modern plant also acts as a regional production hub for Sika national subsidiaries in the neighboring countries Croatia, Slovenia, Hungary, Bosnia and Herzegovina, and Bulgaria. Ivo Schädler, EMEA Regional Manager: “By investing in

Norsk Hydro: Second quarter 2019: Results down on lower realized prices23.7.2019 06:59:00 CESTPress release

Hydro's underlying earnings before financial items and tax was NOK 875 million in the second quarter, down from NOK 2,713 million in the same quarter last year. This mainly reflected lower realized aluminium and alumina prices and effects from the cyber-attack, partly offset by positive currency effects. Underlying EBIT of NOK 875 million Ramp-up progressing successfully at Alunorte, Paragominas and Albras Bauxite & Alumina up on increased production and currency, mostly offset by lower realized alumina prices Primary Metal down on lower realized aluminium price Financial impact of cyber-attack estimated to NOK 250-300 million in Q2 – main impact in Extruded Solutions Downstream results down on margin and volume, reflecting softening demand Energy down on lower volumes 2019 global primary aluminium market expected in deficit, demand growth expectations for 2019 reduced to 1-2% Underlying EBIT for Bauxite & Alumina increased compared to the second quarter of last year, from NOK 364 mill